{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T12:52:39Z","timestamp":1790945559168,"version":"4.1.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100014103","name":"Key Technology Research and Development Program of Shandong","doi-asserted-by":"publisher","award":["2024CXPT084"],"award-info":[{"award-number":["2024CXPT084"]}],"id":[{"id":"10.13039\/100014103","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014103","name":"Key Technology Research and Development Program of Shandong","doi-asserted-by":"publisher","award":["2025CXPT040"],"award-info":[{"award-number":["2025CXPT040"]}],"id":[{"id":"10.13039\/100014103","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012905","name":"Department of Science and Technology of Shandong Province","doi-asserted-by":"publisher","award":["2021CXGC011102"],"award-info":[{"award-number":["2021CXGC011102"]}],"id":[{"id":"10.13039\/100012905","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007785","name":"Jinan Science and Technology Bureau","doi-asserted-by":"publisher","award":["202134019"],"award-info":[{"award-number":["202134019"]}],"id":[{"id":"10.13039\/100007785","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015507","name":"Shandong First Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015507","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82071035"],"award-info":[{"award-number":["82071035"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373424"],"award-info":[{"award-number":["82373424"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82371165"],"award-info":[{"award-number":["82371165"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172866"],"award-info":[{"award-number":["82172866"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2024ZD0525900"],"award-info":[{"award-number":["2024ZD0525900"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.clgc.2026.102545","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T16:50:16Z","timestamp":1773939016000},"page":"102545","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prognostic Significance of Circulating Tumor DNA in Metastatic Prostate Cancer: A Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"24","author":[{"given":"Duming","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianchong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meicheng","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyue","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ligang","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8520-9556","authenticated-orcid":false,"given":"Xiaorong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clgc.2026.102545_bib0001","first-page":"7","article-title":"Cancer statistics","volume":"71","author":"Siegel","year":"2021","journal-title":"CA: A Cancer J Clin"},{"issue":"3","key":"10.1016\/j.clgc.2026.102545_bib0002","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: A Cancer J Clin"},{"issue":"4","key":"10.1016\/j.clgc.2026.102545_bib0003","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"71","author":"Mottet","year":"2017","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.clgc.2026.102545_bib0004","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer","volume":"71","author":"Cornford","year":"2017","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.clgc.2026.102545_bib0005","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.eururo.2018.03.028","article-title":"Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology","volume":"75","author":"Nuhn","year":"2019","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.clgc.2026.102545_bib0006","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"New Engl J Med"},{"issue":"2","key":"10.1016\/j.clgc.2026.102545_bib0007","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.eururo.2016.07.032","article-title":"Enzalutamide in men with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study","volume":"71","author":"Beer","year":"2017","journal-title":"Eur Urol"},{"issue":"9747","key":"10.1016\/j.clgc.2026.102545_bib0008","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"De Bono","year":"2010","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.clgc.2026.102545_bib0009","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.eururo.2017.06.021","article-title":"Three-year safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases from phase 3 randomized alpharadin in symptomatic prostate cancer trial","volume":"73","author":"Parker","year":"2018","journal-title":"Eur Urol"},{"issue":"10459","key":"10.1016\/j.clgc.2026.102545_bib0010","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.clgc.2026.102545_bib0011","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.juro.2016.08.103","article-title":"Prostate specific antigen and prostate cancer in Chinese men undergoing initial prostate biopsies compared with western cohorts","volume":"197","author":"Chen","year":"2017","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.clgc.2026.102545_bib0012","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ajur.2015.04.022","article-title":"Percent free prostate-specific antigen for prostate cancer diagnosis in Chinese men with a PSA of 4.0\u201310.0 ng\/mL: results from the Chinese prostate cancer consortium","volume":"2","author":"Chen","year":"2015","journal-title":"Asian J Urol"},{"issue":"1","key":"10.1016\/j.clgc.2026.102545_bib0013","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13045-022-01351-y","article-title":"Liquid biopsy: current technology and clinical applications","volume":"15","author":"Nikanjam","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"5","key":"10.1016\/j.clgc.2026.102545_bib0014","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41571-020-00457-x","article-title":"Liquid biopsy enters the clinic\u2014implementation issues and future challenges","volume":"18","author":"Ignatiadis","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"10.1016\/j.clgc.2026.102545_bib0015","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/s41585-023-00725-2","article-title":"Circulating and urinary tumour DNA in urothelial carcinoma\u2014upper tract, lower tract and metastatic disease","volume":"20","author":"Rose","year":"2023","journal-title":"Nat Rev Urol"},{"issue":"6","key":"10.1016\/j.clgc.2026.102545_bib0016","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1097\/JS9.0000000000001372","article-title":"Prognostic significance of circulating tumor DNA in urothelial carcinoma: a systematic review and meta-analysis","volume":"110","author":"Liu","year":"2024","journal-title":"Int J Surg"},{"issue":"3","key":"10.1016\/j.clgc.2026.102545_bib0017","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s10555-016-9629-x","article-title":"Origins, structures, and functions of circulating DNA in oncology","volume":"35","author":"Thierry","year":"2016","journal-title":"Cancer Metast Rev"},{"issue":"4","key":"10.1016\/j.clgc.2026.102545_bib0018","first-page":"1659","article-title":"DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells","volume":"61","author":"Jahr","year":"2001","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.clgc.2026.102545_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e13827","article-title":"Prognostic value of genomic mutations in metastatic prostate cancer","volume":"9","author":"Zhu","year":"2023","journal-title":"Heliyon"},{"issue":"7","key":"10.1016\/j.clgc.2026.102545_bib0020","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1038\/s41588-019-0451-6","article-title":"Publisher correction: the long tail of oncogenic drivers in prostate cancer","volume":"51","author":"Armenia","year":"2019","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.clgc.2026.102545_bib0021","doi-asserted-by":"crossref","first-page":"270","DOI":"10.21147\/j.issn.1000-9604.2022.03.07","article-title":"National guidelines for diagnosis and treatment of prostate cancer 2022 in China (English version)","volume":"34","year":"2022","journal-title":"Chin J Cancer Res"},{"issue":"14","key":"10.1016\/j.clgc.2026.102545_bib0022","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/pros.23219","article-title":"A pilot study of clinical targeted next generation sequencing for prostate cancer: consequences for treatment and genetic counseling","volume":"76","author":"Cheng","year":"2016","journal-title":"Prostate"},{"issue":"11","key":"10.1016\/j.clgc.2026.102545_bib0023","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.26921","article-title":"Association of circulating tumor DNA with disease-free survival in breast cancer: a systematic review and meta-analysis","volume":"3","author":"Cullinane","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clgc.2026.102545_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103187","article-title":"Circulating tumour DNA and melanoma survival: a systematic literature review and meta-analysis","volume":"157","author":"Gandini","year":"2021","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"10.1016\/j.clgc.2026.102545_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103771","article-title":"Prognostic potential of circulating tumor DNA detection at different time periods in resectable non-small cell lung cancer: evidence from a meta-analysis","volume":"177","author":"Wang","year":"2022","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"10.1016\/j.clgc.2026.102545_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102362","article-title":"Prognostic value of ctDNA detection in patients with early breast cancer undergoing neoadjuvant therapy: a systematic review and meta-analysis","volume":"104","author":"Papakonstantinou","year":"2022","journal-title":"Cancer Treatment Rev"},{"issue":"12","key":"10.1016\/j.clgc.2026.102545_bib0027","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241210230","article-title":"Circulating tumor DNA as a minimal residual disease assessment and recurrence risk in patients undergoing curative-intent resection with or without adjuvant chemotherapy in colorectal cancer: a systematic review and meta-analysis","volume":"24","author":"Chidharla","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.clgc.2026.102545_bib0028","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005854","article-title":"Changes in circulating tumor DNA and outcomes in solid tumors treated with immune checkpoint inhibitors: a systematic review","volume":"11","author":"Al-Showbaki","year":"2023","journal-title":"J ImmunoTher Cancer"},{"issue":"9","key":"10.1016\/j.clgc.2026.102545_bib0029","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.7150\/ijbs.44024","article-title":"Circulating tumor DNA as an emerging liquid biopsy biomarker for early diagnosis and therapeutic monitoring in hepatocellular carcinoma","volume":"16","author":"Wu","year":"2020","journal-title":"Int J Biologic Sci"},{"key":"10.1016\/j.clgc.2026.102545_bib0030","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"15","key":"10.1016\/j.clgc.2026.102545_bib0031","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology A proposal for reporting","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.clgc.2026.102545_bib0032","doi-asserted-by":"crossref","first-page":"j4008","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.clgc.2026.102545_bib0033","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/jebm.12141","article-title":"The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review","volume":"8","author":"Zeng","year":"2015","journal-title":"J Evidence-Based Med"},{"issue":"6","key":"10.1016\/j.clgc.2026.102545_bib0034","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1016\/j.euo.2025.02.002","article-title":"Prognostic value of the circulating tumor DNA fraction in metastatic castration-resistant prostate cancer: Results from the ProBio platform trial","volume":"8","author":"Crippa","year":"2025","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2026.102545_bib0035","doi-asserted-by":"crossref","first-page":"425","DOI":"10.4314\/tjpr.v21i2.28","article-title":"Treatment efficacy of carrelizumab in metastatic castration-resistant prostate cancer, and the significance of circulating tumor DNA fraction","volume":"21","author":"Zhou","year":"2022","journal-title":"Trop J Pharmaceut Res"},{"issue":"6","key":"10.1016\/j.clgc.2026.102545_bib0036","doi-asserted-by":"crossref","first-page":"564.e1","DOI":"10.1016\/j.clgc.2021.07.012","article-title":"Analysis of the prognostic significance of circulating tumor DNA in metastatic castrate resistant prostate cancer","volume":"19","author":"Shaya","year":"2021","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"10.1016\/j.clgc.2026.102545_bib0037","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54847-1","article-title":"AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patients","volume":"15","author":"Knutson","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.clgc.2026.102545_bib0038","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.euros.2023.05.008","article-title":"AR and PI3K genomic profiling of cell-free DNA can identify poor responders to lutetium-177-PSMA among patients with metastatic castration-resistant prostate cancer","volume":"53","author":"Vanwelkenhuyzen","year":"2023","journal-title":"Eur Urol Open Sci"},{"issue":"16","key":"10.1016\/j.clgc.2026.102545_bib0039","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1158\/1078-0432.CCR-21-0358","article-title":"Blood biomarker landscape in patients with high-risk nonmetastatic castration-resistant prostate cancer treated with apalutamide and androgen-deprivation therapy as they progress to metastatic disease","volume":"27","author":"Smith","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"18","key":"10.1016\/j.clgc.2026.102545_bib0040","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1158\/1078-0432.CCR-24-1096","article-title":"Circulating tumor DNA assessment for treatment monitoring adds value to PSA in metastatic castration-resistant prostate cancer","volume":"30","author":"Sweeney","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.clgc.2026.102545_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103684","article-title":"Durable benefit from poly(ADP-ribose) polymerase inhibitors in metastatic prostate cancer in routine practice: biomarker associations and implications for optimal clinical next-generation sequencing testing","volume":"9","author":"Triner","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.clgc.2026.102545_bib0042","doi-asserted-by":"crossref","first-page":"101701","DOI":"10.1016\/j.tranon.2023.101701","article-title":"Early serial circulating tumor DNA sequencing predicts the efficacy of chemohormonal therapy in patients with metastatic hormone-sensitive prostate cancer","volume":"34","author":"Du","year":"2023","journal-title":"Transl Oncol"},{"key":"10.1016\/j.clgc.2026.102545_bib0043","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1202277","article-title":"Genomic amplifications identified by circulating tumor DNA analysis guide prognosis in metastatic castration-resistant prostate cancer","volume":"13","author":"Dincman","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.clgc.2026.102545_bib0044","article-title":"Prevalence and spectrum of AR ligand-binding domain mutations detected in circulating-Tumor DNA across disease states in men with metastatic castration-resistant Prostate Cancer","volume":"8","author":"Antonarakis","year":"2024","journal-title":"JCO Precis Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2026.102545_bib0045","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1093\/clinchem\/hvac224","article-title":"Prognostic value of low-pass whole genome sequencing of circulating tumor DNA in metastatic castration-resistant prostate cancer","volume":"69","author":"N\u00f8rgaard","year":"2023","journal-title":"Clin Chem"},{"issue":"5_suppl","key":"10.1016\/j.clgc.2026.102545_bib0046","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1200\/JCO.2025.43.5_suppl.214","article-title":"The prognostic significance of circulating tumor DNA in prostate cancer: a systematic review and meta-analysis","volume":"43","author":"Liu","year":"2025","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.clgc.2026.102545_bib0047","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2017.77.6880","article-title":"Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study","volume":"36","author":"Aggarwal","year":"2018","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clgc.2026.102545_bib0048","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s11912-018-0707-9","article-title":"Molecular subtypes of prostate cancer","volume":"20","author":"Arora","year":"2018","journal-title":"Curr Oncol Rep"},{"issue":"2","key":"10.1016\/j.clgc.2026.102545_bib0049","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/path.5652","article-title":"Androgen receptor enhancer amplification in matched patient-derived xenografts of primary and castrate-resistant prostate cancer","volume":"254","author":"Porter","year":"2021","journal-title":"J Pathol"},{"issue":"11","key":"10.1016\/j.clgc.2026.102545_bib0050","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1001\/jamaoncol.2016.1828","article-title":"Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer","volume":"2","author":"Scher","year":"2016","journal-title":"JAMA Oncol"},{"issue":"312","key":"10.1016\/j.clgc.2026.102545_bib0051","doi-asserted-by":"crossref","first-page":"312re10","DOI":"10.1126\/scitranslmed.aac9511","article-title":"Plasma AR and abiraterone-resistant prostate cancer","volume":"7","author":"Romanel","year":"2015","journal-title":"Sci Transl Med"},{"issue":"20","key":"10.1016\/j.clgc.2026.102545_bib0052","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1101\/gad.16962311","article-title":"The cyclin K\/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes","volume":"25","author":"Blazek","year":"2011","journal-title":"Genes Developm"},{"issue":"5","key":"10.1016\/j.clgc.2026.102545_bib0053","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1080\/14728222.2021.1951226","article-title":"Aberrations of DNA repair pathways in prostate cancer: a cornerstone of precision oncology","volume":"25","author":"Boussios","year":"2021","journal-title":"Expert Opin Ther Targets"},{"issue":"5","key":"10.1016\/j.clgc.2026.102545_bib0054","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.eururo.2020.03.024","article-title":"Pan-cancer analysis of CDK12 alterations identifies a subset of prostate cancers with distinct genomic and clinical characteristics","volume":"78","author":"Nguyen","year":"2020","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.clgc.2026.102545_bib0055","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.eururo.2019.09.036","article-title":"Clinical outcomes in cyclin-dependent kinase 12 mutant advanced prostate cancer","volume":"77","author":"Reimers","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2026.102545_bib0056","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1200\/PO.19.00399","article-title":"CDK12-Altered Prostate Cancer: Clinical features and therapeutic outcomes to standard systemic therapies, Poly (ADP-Ribose) Polymerase inhibitors, and PD-1 inhibitors","volume":"4","author":"Antonarakis","year":"2020","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2026.102545_bib0057","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1038\/s41467-022-30257-z","article-title":"MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets","volume":"13","author":"Qiu","year":"2022","journal-title":"Nat Commun"},{"issue":"25","key":"10.1016\/j.clgc.2026.102545_bib0058","doi-asserted-by":"crossref","first-page":"4977","DOI":"10.1038\/s41388-019-0768-8","article-title":"A positive role of c-myc in regulating androgen receptor and its splice variants in prostate cancer","volume":"38","author":"Bai","year":"2019","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.clgc.2026.102545_bib0059","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.cell.2018.10.019","article-title":"Genomic hallmarks and structural variation in metastatic prostate cancer","volume":"175","author":"Quigley","year":"2018","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.clgc.2026.102545_bib0060","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.eururo.2018.12.042","article-title":"Circulating tumor DNA abundance and potential utility in de novo metastatic prostate cancer","volume":"75","author":"Vandekerkhove","year":"2019","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.clgc.2026.102545_bib0061","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/2159-8290.CD-17-0867","article-title":"Identification of Pik3ca mutation as a genetic driver of prostate cancer that cooperates with pten loss to accelerate progression and castration-resistant growth","volume":"8","author":"Pearson","year":"2018","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.clgc.2026.102545_bib0062","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.eururo.2015.11.022","article-title":"Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer","volume":"69","author":"Cheng","year":"2016","journal-title":"Eur Urol"},{"issue":"18","key":"10.1016\/j.clgc.2026.102545_bib0063","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-Repair defects and olaparib in metastatic Prostate Cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.clgc.2026.102545_bib0064","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"issue":"14","key":"10.1016\/j.clgc.2026.102545_bib0065","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2012.43.1882","article-title":"Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer","volume":"31","author":"Castro","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2026.102545_bib0066","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.eururo.2014.10.022","article-title":"Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer","volume":"68","author":"Castro","year":"2015","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.clgc.2026.102545_bib0067","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1200\/JCO.18.00358","article-title":"PROREPAIR-B: a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer","volume":"37","author":"Castro","year":"2019","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2026.102545_bib0068","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.eururo.2019.02.002","article-title":"Differential response to olaparib treatment among men with metastatic castration-resistant prostate cancer harboring BRCA1 or BRCA2 versus ATM mutations","volume":"76","author":"Marshall","year":"2019","journal-title":"Eur Urol"},{"issue":"12","key":"10.1016\/j.clgc.2026.102545_bib0069","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1158\/2159-8290.CD-20-0047","article-title":"Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade","volume":"10","author":"Zhang","year":"2020","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.clgc.2026.102545_bib0070","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s41467-020-20493-6","article-title":"Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer","volume":"12","author":"Vandekerkhove","year":"2021","journal-title":"Nat Commun"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000455?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000455?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T14:30:00Z","timestamp":1778941800000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767326000455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":70,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1558767326000455"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102545","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic Significance of Circulating Tumor DNA in Metastatic Prostate Cancer: A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102545","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102545"}}